 |
Rockville, Maryland, USA and Suzhou, ChinaMay 28, 2026 /PRNewswire/ — Ascentage Pharma (Nasdaq: AAPG; HKEX: 6855), a leading biopharmaceutical company dedicated to developing innovative drugs in oncology and other fields, announced that, as the company has met the market capitalization/revenue requirements under Rule 8.05(3) of the Hong Kong Stock Exchange (HKEX) Listing Rules, it has recently received approval from the HKEX to officially remove the “B” marker from its stock code effective June 1, 2026. This adjustment signifies that Ascentage Pharma has achieved higher standards in terms of market capitalization and revenue, marking another major milestone in the company’s development journey.
Ascentage Pharma was listed on the Main Board of the Hong Kong Stock Exchange under Chapter 18A on October 28, 2019, and was subsequently included in the Shenzhen-Hong Kong Stock Connect and Shanghai-Hong Kong Stock Connect lists. The removal of the “B” marker is regarded as a significant indicator of the growth and development of an 18A biotech company, signifying that the company has met higher standards in market capitalization and revenue. It represents comprehensive recognition of the company’s innovation capabilities, commercialization strength, and development prospects. Based on the primary commercial contributions of its two core products, Noltec® and Lisentuo®, Ascentage Pharma’s annual revenue for 2025 reached RMB 574 million.
Dr. Yang Dajun, Chairman and CEO of Ascentage Pharma, stated: “This successful removal of the ‘B’ marker is a significant recognition of Ascentage Pharma’s commercialization capabilities and market performance, and it powerfully demonstrates the company’s global innovation strength. As a global biopharmaceutical company with dual primary listings on the Hong Kong Stock Exchange and Nasdaq, we will continue to focus on unmet patient needs, accelerate the global clinical development of our core products, and strive to become a global leader in the field of hematologic malignancies, bringing greater benefits to patients worldwide and creating more value for shareholders and society.”
About Ascentage Pharma
Ascentage Pharma (Nasdaq: AAPG; HKEX: 6855) is a comprehensive global biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative drugs to address unmet clinical needs of patients worldwide in the oncology field. The company has established a rich pipeline of innovative drug candidates, including inhibitors targeting key proteins in the apoptosis pathway such as Bcl-2 and MDM2-p53, next-generation inhibitors targeting kinase mutants arising in cancer treatment, and protein degraders.
The company’s core product, Noltec®, is the first approved third-generation BCR-ABL inhibitor in China, approved for the treatment of adult patients with chronic myeloid leukemia in chronic phase (CML-CP) and accelerated phase (CML-AP) harboring the T315I mutation, as well as adult patients with CML-CP who are resistant and/or intolerant to first- and second-generation TKIs. All approved indications for this drug have been included in China’s National Reimbursement Drug List (NRDL). Currently, Ascentage Pharma is conducting three global registrational Phase III clinical studies for Noltec®: the POLARIS-1 study, authorized by the U.S. FDA and the European EMA, evaluating Noltec® in the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients; the POLARIS-2 study, authorized by the U.S. FDA and the European EMA, evaluating Noltec® in the treatment of pretreated adult CML-CP patients; and the POLARIS-3 study, evaluating Noltec® in the treatment of SDH-deficient GIST patients.
The company’s other significant product, Lisentuo®, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisentuo® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. Currently, Ascentage Pharma is conducting four global registrational Phase III clinical studies for Lisentuo®: the GLORA study, authorized by the U.S. FDA and the European EMA, evaluating Lisentuo® in combination with a BTK inhibitor in CLL/SLL patients who have received prior BTK inhibitor therapy for more than 12 months and have had a suboptimal response; the GLORA-2 study, evaluating Lisentuo® as a first-line treatment for treatment-naïve CLL/SLL patients; the GLORA-3 study, evaluating Lisentuo® as a first-line treatment for newly diagnosed elderly or unfit AML patients; and the GLORA-4 study, authorized by the U.S. FDA and the European EMA, evaluating Lisentuo® as a first-line treatment for newly diagnosed intermediate- and high-risk MDS patients.
Leveraging its strong research and development capabilities, Ascentage Pharma has established a global intellectual property layout and has entered into global collaborations with numerous leading biopharmaceutical companies, including Takeda, AstraZeneca, Merck & Co., Pfizer, and Innovent, as well as academic institutions such as Dana-Farber Cancer Institute, Mayo Clinic, the National Cancer Institute, and the University of Michigan. For more information, please visit https://ascentage.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact in this press release may constitute forward-looking statements, including opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events, operating results, or financial condition of Ascentage Pharma.
These forward-looking statements are subject to numerous risks and uncertainties, as detailed in documents filed by Ascentage Pharma with the U.S. Securities and Exchange Commission (SEC), including the sections titled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed on April 29, 2026, the sections titled “Forward-Looking Statements” and “Risk Factors” in its initial public offering prospectus filed on October 16, 2019, and other documents we file from time to time with the SEC or HKEX. These factors could cause actual results, performance, operating results, or achievements to differ materially from those expressed or implied in the forward-looking statements. The statements in this forward-looking statement do not constitute a profit forecast by the company’s management.
Accordingly, such forward-looking statements should not be regarded as predictions of future events. The forward-looking statements in this press release are based solely on Ascentage Pharma’s current expectations and judgments regarding future developments and their potential impact and speak only as of the date of such statements. Ascentage Pharma undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.